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ABSTRACT
Objectives: To analyse the effect of women’s
characteristics on their willingness to join a blind or a
non-blind subtrial or to be excluded by physicians.
Design: Primary prevention trial of postmenopausal
hormone therapy (HT). A 2×2, randomised design with
a non-blind HT arm or control arm and a blind HT arm
or placebo arm.
Setting: 3 clinical centres in Estonia.
Methods: Interest in joining the trial was asked in a
questionnaire together with demographic and health
status data. Interested and eligible women were invited
to a health examination that also informed whether
they belonged to a blind or to a non-blind subtrial; the
arm was not revealed. Trial physicians made further
exclusions when checking the women’s eligibility.
Thereafter, informed consent was asked as detailed in
the flow chart. Comparisons were made between non-
blind and blind subtrials. Analyses were carried out for
each of the background variables.
Outcome measures: The proportion of willingness,
eligibility and attendance.
Results: Women randomised to the non-blind
subtrial were more willing to join (relative risk (RR)
1.17) and more likely to be found eligible by
physicians (RR 1.10) than women in the blind
subtrial, resulting in larger attendance (RR 1.29).
Women with higher education were differentially
more willing to join the non-blind trial (RR 1.29)
than those with basic education (RR 1.08); the
differential willingness of never-smokers (RR 1.20)
was larger than that of current smokers (RR 1.07).
The differential exclusion by physicians by
education and smoking were small. Some subjective
symptoms (eg, diarrhoea/constipation, stomach pain)
had reverse differential effects on attendance in the
non-blind subtrial in comparison to the blind
subtrial. Menopausal symptoms did not affect the
differential interest, eligibility or attendance.
Conclusions: Blinding in RCT reduces attendance,
due to decisions of the women and the trial
physicians. Differential attendance by blinding
may affect the generalisability of the results from
trials.
Trial registration number: ISRCTN35338757.
INTRODUCTION
The Estonian Postmenopausal Hormone
Therapy (EPHT) Trial was a primary preven-
tion trial of postmenopausal hormone
therapy (HT) carried out in three clinical
centres in Estonia from 1999 to 2014. The
objective of the EPHT Trial was to assess the
effect of HT on the use of health services
and on the health of the women. To achieve
the ﬁrst objective, we designed randomisa-
tion without blinding, while blinding was an
essential dimension in the design of the
second objective. Therefore, randomisation
was carried out in a 2×2 design, which
enabled us to evaluate the effect of blinding
itself. Women were randomised into blind
and non-blind subtrials, which were disclosed
before the ultimate conﬁrmation of willing-
ness and signing of the informed consent. At
the ﬁnal assessment of eligibility, the trial
physicians also knew whether the woman
belonged to the blind or non-blind subtrial.
Several authors have shown that inad-
equate allocation concealment or lack of
blinding can result in biased estimates of
intervention outcomes, especially in trials
with subjective outcomes.1 2 Non-blind trials
tend to exaggerate the effect size,3 4 but the
degree of bias may vary.4 5 So far as we know,
studies looking at whether participants in
blind and non-blind trials differ by their
Strengths and limitations of this study
▪ Two subtrials, blind and non-blind, which were
run in parallel, were compared.
▪ The effect of participants’ characteristics on
recruitment in blind versus non-blind trials has
not been studied previously.
▪ It is difficult to separate women’s and physicians’
decisions.
▪ Only a limited number of characteristics were
compared.
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background characteristics and how the different back-
ground characteristics affect recruitment into blind and
non-blind trials have never been published before.
We have previously shown6 in a preventive postmeno-
pausal HT trial that the ﬁnal attendance was about 30%
larger in the non-blind arm subtrial than in the blind
subtrial. In a previous article,7 we found that both
during the trial period and follow-up, more cases of cor-
onary heart disease, cancer, cerebrovascular disease,
bone fractures and total deaths were observed in the
controls of the non-blind subtrial than in the blind sub-
trial placebo arm. Disease-speciﬁc differences in out-
comes were not statistically signiﬁcant, but taken
together the consistency in the differences could not be
accounted for by random variation.
In this paper, we compare the effects of background
characteristics of women on the difference in willingness
to make the recruitment visit and second on the exclu-
sions made by the trial physician during the recruitment
visit in the non-blind subtrial compared with the blind
subtrial. Finally, the ﬁnal effect of the same background
characteristics when being recruited among all rando-
mised women was compared between the non-blind and
blind subtrial.
METHODS
The data were obtained from the recruitment process in
the EPHT Trial. This was a randomised trial on the
effect of HT on health outcomes,8 use of health services9
and quality of life.10 Recruitment to the trial was
conducted by means of a questionnaire sent to all
50–64 years old Estonian-speaking women in two areas,
Tallinn and Tartu and their surrounding counties
(n=39 713, ﬁgure 1) in 1999. Names and addresses were
obtained from the population register. A detailed
description of the recruitment process has been pub-
lished elsewhere.11
Attached to the recruitment questionnaire was a
two-page leaﬂet explaining the need for the trial and
describing the assumed or known beneﬁcial and
harmful effects of postmenopausal HT. The trial design
was described in general terms, saying that those inter-
ested would be randomly allocated into three groups:
HT, placebo and no treatment. The questionnaire asked
about women’s health, background characteristics and
interest in joining the trial (Do you want to participate
in a trial on postmenopausal therapy as described in the
enclosed leaﬂet?). Those interested but found to be
ineligible on the basis of the questionnaire data were
sent a thank you letter stating the reasons for their ineli-
gibility. Figure 1 shows that 14 982 women returned the
recruitment questionnaire, and from those 6606 women
showed ﬁrst stage interest in joining the trial according
to the returned recruitment questionnaire, with 4295 eli-
gible according to the recruitment questionnaire (ﬁrst
stage eligibility). The randomised 124 pilot group
women were not included in the present analysis due to
their different background characteristics, leaving 4171
women in the present analyses.
The exclusion criteria in the recruitment question-
naire were as follows: last menstrual period <12 months
ago, no valid health insurance, use of HT in past
6 months, myocardial infarction in past 6 months, hepa-
titis or functional liver disorder in past 3 months, cere-
bral infarction, pulmonary embolism, deep vein
thrombosis, endometriosis, porphyry ever, endometrial
cancer, ovarian cancer, breast cancer or meningioma
ever and any other form of cancer in the past 5 years.
The interested and potentially eligible women
(n=4171) were randomised into four arms (blind sub-
trial with options of blind HT or placebo and non-blind
subtrial, with the options of open-label HT or no treat-
ment arms) by clinic (three clinics). Randomisation was
performed from 1999 to 2001 in seven batches, using a
computer-based stratiﬁed block randomisation program
(block size 16). The code of treatment was sealed in a
fully opaque envelope.
Each of the 4171 women was sent a personal invitation
letter, indicating whether they were in a blind or non-
blind subtrial. It advised the woman to phone the study
midwife at the clinic to make an appointment for a clin-
ical examination by a trial physician. If the woman
invited did not respond, a coordinating study physician
invited her by telephone. Starting with the third recruit-
ment batch, if the woman had not been reached by tele-
phone, a reminder letter was sent asking her to make an
appointment. Altogether 2323 of the 4171 women
arrived for the health check-up (second stage interest in
joining the trial). In total, 833 women in the non-blind
subtrial and 1015 in the blind arm did not show up at
the clinic (see ﬁgure 1).
The study physicians (eight altogether) were given
detailed instructions on what to ask and measure, and
what were the exclusion criteria (in addition to those
listed above, untreated hypertension or hypertension
resistant to drug therapy, irregular postmenopausal
bleeding, abnormal PAP-screen result, menstrual bleed-
ing within the past 12 months, desire for HT, or plans to
move out of the area). Determining eligibility required
two visits to the clinic, since some examination results
were not ready at the ﬁrst visit.
At the clinic the envelope containing the code for the
treatment arm was opened after signing the informed
consent form. The envelope contained a drug sheet for
the midwife and a one-page leaﬂet to be given to the
woman. This leaﬂet again explained the study design
and the method of taking or not taking the drug, and
described potential adverse effects and any symptoms
that would necessitate contacting the study physician or
an emergency clinic.
In the blind subtrial, women were told that they would
remain blind with regard to the HT or placebo arms
until the end of the trial. Women in the HT arm of the
non-blind subtrial were told that they would be receiving
HT. Women in the control arm were told that they
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would receive no treatment, but they were asked to ﬁll
in the annual questionnaires and pay a visit to the trial
physician.
The ultimate willingness (third stage interest and
second stage eligibility) was conﬁrmed by written
consent. The ﬁnal numbers of women who consented
were 494 in the non-blind HT arm, 507 in the non-blind
control arm, 404 in the blind HT arm and 373 in the
blind placebo arm. All trial participants signed the
informed consent form. In the written consent form, all
women accepted that they would be additionally fol-
lowed through registries.
Figure 1 Flow chart on
randomisation in the EPHT Trial.
EPHT, Estonian Postmenopausal
Hormone Therapy; HT, hormone
therapy.
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The outcome variables were the proportion of willing-
ness, eligibility and attendance. Willingness was esti-
mated as the proportion of women who paid the
recruitment visit (n=2323) among all randomised
women (4171; second stage interest). Eligibility was esti-
mated as the proportion of women who ultimately
joined the trial (n=1778) among all who paid the
recruitment visit (n=2323; third stage interest and
second stage eligibility). Attendance was estimated as the
proportion of women who ﬁnally joined the trial
(n=1778) among all randomised women (n=4171).
The analyses were stratiﬁed by each of the background
variables. Information on different background factors
was obtained from the recruitment questionnaires.
As a measure of the differential effect of the back-
ground characteristics, the corresponding relative prob-
abilities (abbreviated RR for ‘relative risk’) of any of the
outcome variables in the non-blind versus the blind sub-
trial in each stratum deﬁned by the background
characteristics were used. Thus, an RR>1 indicates that
blinding makes the trial less ‘attractive’ to women with
the characteristic in question. We use the terms relative
probabilities, differential (relative) risk, differential
outcome (willingness, eligibility, attendance) and differ-
ential effect interchangeably. Ninety-ﬁve per cent CIs for
relative probabilities (RR) were calculated using the
standard formula, based on asymptotic normality of
logarithmic RR.12
RESULTS
The woman’s overall willingness was higher if the
woman was in the non-blind subtrial (RR 1.17 non-blind
vs blind). There were lesser exclusions in the non-blind
arm, resulting in higher overall eligibility (RR 1.10, non-
blind vs blind). Thus, the attendance was higher in the
non-blind arm than in the blind arm (RR 1.29). All
strata-speciﬁc outcomes regarding differential willing-
ness, eligibility and attendance can be compared with
these reference values (presented also in the tables as
totals).
Women with higher education had a higher willing-
ness to join the non-blind subtrial (RR 1.29) than those
with secondary education (RR 1.13) or basic education
(RR 1.08; table 1). Differential eligibility was quite
similar in all educational groups. Therefore, the differ-
ential attendance was highest among women with
higher education.
The selection was different by marital status: the vari-
ation in different risk was about 17% (RR from 0.98 to
1.15) in eligibility, whereas the variation in willingness
was only 5% (RR from 1.13 to 1.18). The differential
attendance according to marital status varied from 1.11
to 1.33. The differential attendance was low among
single women and rather uniform in other marital
groups.
Never-smokers had a higher differential willingness
than current or former smokers (RR 1.20, 1.07, 1.15,
respectively). The differential eligibility was also highest
among non-smokers (RR 1.11, 1.05, 1.08). Therefore,
the same trend remained in the ultimate attendance
(RR 1.34, 1.15, 1.21, respectively).
The presence of respiratory and gastrointestinal symp-
toms had a stronger effect on exclusion from the blind
subtrial compared with the non-blind subtrial.
Willingness was higher in the non-blind subtrial regard-
less of the presence of these symptoms, and the same
applied to eligibility, for example, the differential eligi-
bility when comparing the lack-of-breath symptom was
1.06 if the symptom was not reported and 1.22 if the
woman had reported the symptom (table 2). The differ-
ential eligibility for women with and without stomach
ache was 1.28 and 1.07, respectively, and for women with
and without diarrhoea/constipation, it was 1.22 and
1.06, respectively.
Hot ﬂushes are one of the main reasons for meno-
pausal HT. This symptom did not differentiate with
regard to willingness (RR 1.17 in those with or without
the symptom). In eligibility there was a small differential
preference in favour of the non-blind subtrial in those
without the symptom (RR 1.12 vs 1.06). The attendance
rates for women with or without hot ﬂushes did not
differ much between the blind and non-blind subtrial
(RR 1.31 and 1.27, respectively). Sweating, another
typical menopausal symptom also showed no
differences.
DISCUSSION
In the EPHT Trial there was an increase in the ultimate
attendance (29%) if the trial was not blind. Both the
women (17%) and the physicians (10%) favoured the
non-blind trial.6 In this paper we show that joining a
blind or non-blind subtrial was affected by the woman’s
background factors, speciﬁcally related to the social pos-
ition of the woman and to her symptoms. The differen-
tial willingness of the woman was more related to her
socioeconomic characteristics, while the eligibility cri-
teria by physicians was more related to the woman’s
symptoms, even if she was not falling in the exclusion
criteria. The more skewed the distribution, the more
selection was caused by these speciﬁc background
characteristics. The main indications of HT, hot ﬂushes
and sweating, did not affect differentially either willing-
ness or eligibility.
Earlier we have shown7 that the risks of coronary
heart diseases, cerebrovascular events, bone fractures,
total mortality and all events together were smaller in
the blind placebo control group than in the non-blind
control group. We hypothesised that this may have
resulted from the selection bias caused by the different
background characteristics of the women, the difference
in seeking medical advice during the trial due to
knowing whether they would receive treatment or not,
or from the delay in diagnosis by physicians due to
blinding. We have now analysed the differential effect of
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women’s background characteristics on willingness, eligi-
bility and attendance during the recruitment process.
The EPHT Trial was conducted several years ago, but
the analysis of the effect of blinding on trial attendance
is not time critical.
The risk factor proﬁle was recorded before the start of
the intervention. Education and smoking are strongly
related to the woman’s socioeconomic position and to
the risk of speciﬁc diseases and overall health. Current
smokers with high risk preferred the non-blind arm,
which is consistent with the low risk of diseases observed
in the blind placebo controls.
The doctor should have applied the symptoms as
exclusion criteria more persistently and more frequently
in the blind than in the non-blind subtrial. This is con-
sistent with the observed disease differences by arm, if
the symptoms predicted the chronic diseases recorded
in the EPHT Trial. However, this potential explanation
was to some extent eliminated by the willingness of a
woman to accept the blind subtrial less consistently if
she had symptoms. The overall effect was not totally
neutral after this interaction and the differences in dis-
eases could possibly be accounted for by the symptoms
and their effect on the woman’s differential eligibility.
Table 1 Relative probabilities (RR, non-blind vs blind subtrial) of the willingness by woman and of the eligibility by doctor
and the ultimate attendance by the woman’s socioeconomic status, EPHT Trial
Socioeconomic status Willingness (95% CI) Eligibility (95% CI) Attendance (95% CI)
Education
Basic 1.08 (0.91 to 1.27) 1.14 (0.97 to 1.34) 1.22 (0.97 to 1.54)
Secondary 1.13 (1.05 to 1.22) 1.09 (1.03 to 1.16) 1.24 (1.13 to 1.36)
Higher 1.29 (1.17 to 1.42) 1.10 (1.02 to 1.18) 1.42 (1.25 to 1.60)
Marital status
Single 1.13 (0.90 to 1.42) 0.98 (0.80 to 1.20) 1.11 (0.82 to 1.50)
Married 1.17 (1.10 to 1.26) 1.10 (1.04 to 1.17) 1.29 (1.18 to 1.42)
Divorced 1.15 (1.01 to 1.32) 1.15 (1.02 to 1.29) 1.33 (1.12 to 1.58)
Widow 1.18 (1.01 to 1.37) 1.08 (0.96 to 1.22) 1.27 (1.05 to 1.55)
Smoking
Never 1.20 (1.13 to 1.28) 1.11 (1.05 to 1.18) 1.34 (1.23 to 1.46)
Former 1.15 (0.92 to 1.24) 1.05 (0.96 to 1.21) 1.21 (0.95 to 1.39)
Current 1.07 (1.00 to 1.32) 1.08 (0.94 to 1.17) 1.15 (1.02 to 1.45)
Total (reference value) 1.17 (1.11 to 1.24) 1.10 (1.05 to 1.15) 1.29 (1.20 to 1.38)
EPHT, Estonian Postmenopausal Hormone Therapy; RR, relative risk.
Table 2 Relative probabilities (RR, non-blinded vs blinded subtrial) of the willingness by woman and of the eligibility by
doctor and the ultimate attendance by the woman’s symptoms, EPHT Trial
Symptom* Willingness (95% CI) Eligibility (95% CI) Attendance (95% CI)
Lack of breath
No 1.21 (1.13 to 1.31) 1.06 (1.00 to 1.13) 1.30 (1.17 to 1.42)
Yes 1.11 (0.97 to 1.27) 1.22 (1.08 to 1.38) 1.36 (1.13 to 1.62)
Diarrhoea or constipation
No 1.12 (1.04 to 1.21) 1.06 (0.99 to 1.13) 1.19 (1.07 to 1.32)
Yes 1.32 (1.17 to 1.47) 1.22 (1.07 to 1.21) 1.55 (1.33 to 1.81)
Stomach pain
No 1.17 (1.09 to 1.26) 1.07 (1.00 to 1.14) 1.25 (1.14 to 1.37)
Yes 1.16 (0.99 to 1.37) 1.28 (1.05 to 1.36) 1.48 (1.17 to 1.88)
Swelling
No 1.20 (1.12 to 1.30) 1.07 (1.03 to 1.21) 1.28 (1.17 to 1.42)
Yes 1.04 (0.91 to 1.19) 1.20 (1.05 to 1.36) 1.24 (1.03 to 1.50)
Hot flushes
No 1.17 (1.07 to 1.28) 1.12 (1.03 to 1.21) 1.31 (1.16 to 1.47)
Yes 1.17 (81.08 to 1.27) 1.06 (1.00 to 1.14) 1.27 (1.12 to 1.38)
Sweating
No 1.16 (1.06 to 1.28) 1.09 (1.01 to 1.19) 1.27 (1.13 to 1.44)
Yes 1.18 (1.08 to 1.28) 1.10 (1.02 to 1.17) 1.29 (1.16 to 1.43)
Total (reference value) 1.17 (1.11 to 1.24) 1.10 (1.05 to 1.15) 1.29 (1.20 to 1.38)
*Those with the symptom unknown are excluded.
EPHT, Estonian Postmenopausal Hormone Therapy; RR, relative risk.
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In summary, it is credible that the background
characteristics of the women attending the EPHT Trial
account for some of the lower risk of trial outcomes in
placebo controls compared with non-blind controls. We
have incorporated the CI in the tables. However, we
hope that the statistical signiﬁcance of the estimates of
selection (RR) were not emphasised too much. This is
because our objective is measured by variation in RR
within a background variable. The magnitude of this
variation is the point: no need to adjust if small;
however, there is need to consider if it is large, inde-
pendent of its signiﬁcance.
We do not know whether the women asked for extra-
neous information to decide whether to join the trial or
not. Anyhow, our design mimics the actual decision-
making of a participant without the direct inﬂuence of
the study investigators. We assume that the willingness
mainly reﬂects the decision of the woman and indicates
the preference for a non-blind trial. It is also possible
that the study physician allowed the discussion with the
participant and her preferences to affect the exclusion
criteria. Thus, the ultimate decision was probably more
or less a combined one by the woman and the doctor.
Participants in randomised controlled trials (RCTs)
have been compared with the general population, and
their lower risk proﬁle has been noted.13 We have previ-
ously shown6 that blinding reduces the willingness of
the participant and eligibility as deﬁned by the trial in
the randomised trial of EPHT. In this paper we have
shown that the difference in attendance was differen-
tially related to the participant’s background character-
istics, which were predictive as to the trial outcome.
Therefore, blinding may have implications for the com-
parability and generalisability of RCTs.
Other aspects of blinding that may affect the trial
results, for example, the effect of blinding on behaviour,
deserves further research. As blinding may have a
notable effect on trial outcomes, this effect should be
taken into account for improving the PRECIS tool14 for
designing pragmatic trials, as well as in the extension of
the CONSORT statement for pragmatic trials.15
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